China has approved clinical trials for two more experimental vaccines to combat the novel coronavirus, officials said Tuesday, as the world’s scientists race to beat the pandemic.
The vaccines use inactivated coronavirus pathogens, and the approvals pave the way for early-stage human trials, Wu Yuanbin, an official from China’s Ministry of Science and Technology told a regular press briefing.
China’s state food and drug administration on Monday approved one vaccine developed by a Beijing-based unit of Nasdaq-listed Sinovac Biotech, Wu said.
Another vaccine, being developed by the Wuhan Institute of Biological Products and the Wuhan Institute of Virology, was approved on Sunday, he added.
China now has three different clinical trials for three possible coronavirus vaccines in the works.
Beijing approved the first trial for a vaccine developed by the military-backed Academy of Military Medical Sciences and Hong Kong-listed biotech firm CanSino Bio on March 16.
That day the US drug developer Moderna said it had begun human tests for their vaccine with the US National Institutes of Health.
“Vaccination of subjects during the first phase of clinical trials and the recruitment of volunteers for the second phase of clinical trials began on April 9,” Wu said.
“It’s the world’s first novel coronavirus vaccine to initiate Phase II clinical studies.”
There are currently no approved vaccines or medication for the COVID-19 disease, which has killedmore than 120,000 people worldwide and infected nearly two million.
Chinese teams were also racing to develop vaccines using other methods including using attenuated influenza virus vectors or injecting specific nucleic acid.
Several of these projects are currently undergoing animal testing and quality inspections, Wu said.
“The vaccines using the above technical methods are expected to be submitted for clinical trials in April and May,” he added.
Experts have raised hopes that a vaccine could be ready within 18 months.
– AFP

Subscribe
Notify of
1 Comment
Newest
Oldest Most Voted
Inline Feedbacks
View all comments
You May Also Like

Typhoon forces re-scheduling at Philippines' SEA Games

Powerful Typhoon Kammuri forced organisers of the Southeast Asian Games in the Philippines to…

【2020财政预算案】前进党:应助百姓纾困应对疫情 正视外籍客工对就业市场影响

昨日(18日),副总理兼财政部长王瑞杰在国会公布2020年财政预算案。 新加坡前进党此前已建议落实扩张性预算案,提升经济和就业机会;提供短期财政援助纾困,同时反对调涨消费税。 对此该党针对政府的财案发表看法,先是感谢政府聆听该党和民间各造的意见,赞许额外拨款8亿元供前线医务人员抗疫的举措。 助理秘书长梁文辉则认为,面对武汉冠状病毒(COVID-19)的冲击下,老百姓家户也应获得额外的纾困减轻负担,因此提出比起现有政府拨款16亿元“关怀与援助配套”相比,应该还能做得更好。 “我们建议至少为本地家户拨款10至20亿元,以协助老百姓应对经济下行和疫情面对的困境。” 该党也强调,财案不应是糖果袋,反之应该是长期性的规划,而不是短期或临时性的财政发放。然而该党认为政府的财案以不同形式的“糖果”派发,也很难让人民理解如何能从中受惠,也缺乏对振兴经济信心的成效。 “经济过于依赖外籍客工” 再者,前进党提醒从疫情的爆发,也可见我国企业和经济面对的一项问题:过于依赖外籍客工。其中这也部分是因为生育率低下造成的,“故此我们应该重新审视,透过提升生育率来增加本地劳动力的更强有力政策” 尽管王瑞杰宣布明年将不会调涨消费税,不过前进党强调该党反对考量当前局势,未来五年都不建议调涨消费税或其他费用。有鉴于政府未言明调涨消费税的时间点(仅表示2025年需调涨),为此该党也质疑政府推出60亿元援助配套的合理性。 “再者,此前政府一再强调调涨消费税之必要。然而如今又得以基于经济困境暂缓,还能拨出逾60亿元的援助配套,且不需动用储备金”。这使得该党质疑未来是否还有调整消费税的理据。 另一方面,政府宣布将S准证持有者比率分两阶段进行调整。从明年1月起,先把顶限调低到18巴仙。到2023年1月,再调低到15巴仙。 正视外籍客工构成职场竞争…

Ben Pwee: Vote with the national political agenda in mind

~By Benjamin Pwee~ We are happy to see Hougang residents having a…